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The prevalence of asthma during pregnancy is estimated
on 4%. Uncontrolled, severe asthma is a risk for both a
mother and an unborn child. Therefore, optimization of
asthma treatment during pregnancy is vital in achieving
good outcomes. Physicians and their patients may have
some doubts about safety of anti-asthmatic medications,
especially if drugs are new. Omalizumab is a humanized
recombinant anti-IgE monoclonal antibody recommended
for the treatment of chronic severe IgE-mediated asthma.
Clinical and observational studies confirmed its effective-
ness in improving asthma control, reducing severe exacer-
bations and improving quality of life. The safety data
concerning pregnancy come from the experimental studies
on animals and they show no teratogenic effect. We pre-
sent case reports of two women who became pregnant
during the treatment with omalizumab. Both with very
severe asthma treated chronically with all available medi-
cation including systemic steroids (first – 20 mg predniso-
lone/day, second – 40 mg prednisolone/day). Both started
their regular treatment with omalizumab in 2007 and have
significant improvement (withdrawal of oral steroids or
significant reduction of their dose, better asthma control) .
First, 32-year old woman became pregnant in 2010 and
gave birth in Oct 2010 - it was her 3rd pregnancy, and 3rd
labor , second 31-year old – also became pregnant in 2010
and gave birth in Jan 2011 - it was her 5th pregnancy and
2nd labor. Both had complications during previous preg-
nancies and labors and decided to continue therapy with
omalizumab. First woman, besides omalizumab, was trea-
ted with high doses of ICS and LABA, second - high doses
of ICS, LABA and 5 mg prednisone/day. The pregnancies
proceeded without asthma exacerbations and other
complications. First woman delivered healthy girl (Apgar
9, weight 3200 g, length 56 cm) in 40 week of pregnancy
by caesarean section due to the narrow pelvis, second -
health boy (Apgar 9, weight 3800 g, length 56 cm) in
40 week by caesarean section due to the aggravating obste-
trical history. In both cases treatment with omalizumab
did not affect pregnancies and newborns.
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